Nchi: Kanada
Lugha: Kiingereza
Chanzo: Health Canada
VERAPAMIL HYDROCHLORIDE
PHARMEL INC
C08DA01
VERAPAMIL
240MG
TABLET (EXTENDED-RELEASE)
VERAPAMIL HYDROCHLORIDE 240MG
ORAL
100
Prescription
MISCELLANEOUS CALCIUM-CHANNEL BLOCKING AGENTS
Active ingredient group (AIG) number: 0113846003; AHFS:
APPROVED
2002-05-30
PRODUCT MONOGRAPH PR PHL-VERAPAMIL SR Verapamil hydrochloride Sustained-Release Tablets, USP 240 mg Antihypertensive Agent PHARMEL INC. 6111 Royalmount Ave., Suite 100 Montréal, Canada H4P 2T4 Date of Revision: July 16, 2013 Submission Control No: 166102 _ _ _phl-VERAPAMIL SR Product Monograph _ _Page 2 of 38_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ..........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE ..............................................................................3 CONTRAINDICATIONS ...................................................................................................4 WARNINGS AND PRECAUTIONS ..................................................................................4 ADVERSE REACTIONS ....................................................................................................9 DRUG INTERACTIONS ..................................................................................................12 DOSAGE AND ADMINISTRATION ..............................................................................18 OVERDOSAGE ................................................................................................................19 ACTION AND CLINICAL PHARMACOLOGY ............................................................21 STORAGE AND STABILITY ..........................................................................................24 DOSAGE FORMS, COMPOSITION AND PACKAGING .............................................24 PART II: SCIENTIFIC INFORMATION ................................................................................25 PHARMACEUTICAL INFORMATION ..........................................................................25 CLINICAL TRIALS ..........................................................................................................26 DETAILED PHARMACOLOGY ......................................... Soma hati kamili